Our Commitment to Fighting COVID-19

Last update: September 28, 2021

Throughout the ongoing pandemic, we have joined forces to fight COVID-19 in every way possible. This includes developing and manufacturing vaccines and manufacturing at large scales to help prevent and control

Paul Hudson

"Despite multiple vaccines becoming available, there remain vast global health needs further exasperated by the unpredictability of virus variants. Sanofi is continuing to complement its expertise and resources with that of our peers to help prevent and control the pandemic over the long term."

Paul Hudson, CEO Sanofi

For over a century, vaccines have been a pillar of medical care. Every vaccine developed to date is based upon the same fundamental principle: by teaching our immune systems to recognize a pathogen and destroy it, we can help protect our bodies from infectious diseases. We are building on this principle to develop vaccines against SARS-CoV-2, the coronavirus that causes COVID-19.

The adjuvanted recombinant protein vaccine candidate. In collaboration with the US BARDA, this vaccine candidate uses our recombinant protein manufacturing platform together with GSK’s pandemic adjuvant platform. It is progressing well in a phase 3 efficacy and safety trial. In parallel, we have expanded our research program to include a study of the vaccine as a potentially broadly protective booster dose. Recently published preclinical data showed that it has the potential to strongly boost immune responses following vaccination with many of the currently approved vaccines and against a broad range of variants.

The mRNA vaccine candidate. Positive interim results from a phase 1/2 study of this candidate confirmed the potential of recently acquired Translate Bio’s mRNA and lipid nanoparticle (LNP) platforms and support Sanofi’s mRNA strategy. Taking into account public health needs and given sufficient mRNA COVID-19 vaccines supply can be expected going forward, we have decided not to pursue the development of our COVID-19 mRNA candidate into a phase 3 clinical study. We will focus our mRNA resources in our newly created mRNA Center of Excellence to address future pandemics and other infectious diseases and therapeutics where there is a strong unmet need.

Thomas Triomphe

"All our decisions are and will always be driven by science and data. We remain confident and committed to developing and manufacturing safe and efficacious COVID-19 vaccine."

Thomas Triomphe, Executive Vice President and Head of Sanofi Pasteur

Supporting global supply

We also keep our commitment to making a strong contribution to current global public health priorities:  the company has begun to support manufacturing and supply of half a billion doses of three different currently approved vaccines: BioNTech’s approved COVID-19 vaccine, co-developed with Pfizer, the vaccine developed by Johnson & Johnson, and the vaccine developed by Moderna.

“The company is working across multiple countries and in coordination with partner manufacturing sites to make vaccines at the extremely large scales required by the pandemic. The manufacturing process is a complex, never-ending job, but our aim is to supply vaccines to as many people as possible,” said Vincent Hingot, Head of Vaccine Industrial Affairs.

Sanofi’s approach to innovation in mRNA Vaccines
Upshot Series Article 5
Developing COVID-19 Vaccines: Behind the Scenes
World immunization week
The People Behind Life-Protecting Vaccines